Výsledky vyhledávání - "Judith K, Sato"

Long-Term Follow-up of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Children and Young Adults with Metastatic or Relapsed Ewing Sarcoma: A Single-Institution Experience

Autor: George T. Calvert, Joseph D. Femino, Clarke P. Anderson, Jerry C. Cheng, Nicole Karras, Julie DiMundo, Joseph Rosenthal, Judith K. Sato, Anna B. Pawlowska, Dongyun Yang, Andrew Dagis, J'Rick Lu, Victoria Sun, James S. Miser

Publikováno v: Transplantation and cellular therapy. 27(1)

Forty-seven patients with metastatic disease at diagnosis or recurrent Ewing sarcoma (EWS) received high-dose chemotherapy (HDC) followed by tandem (n = 20, from February 13, 1997, to October 24, 2002) or single (n = 27, from October 1, 2004, to Sept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c281c1b4988ed52e875daab4e4d245b1
https://pubmed.ncbi.nlm.nih.gov/33007495

Zobrazit plný text záznamu

Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

Autor: Steven E. Lipshultz, Allen M. Goorin, Judith K. Sato, Laurel J. Steinherz, Cindy L. Schwartz, Mark L. Bernstein, Holcombe E. Grier, Lisa A. Teot, Paul A. Meyers, Mark Krailo, Mark C. Gebhardt, Leonard H. Wexler, Meenakshi Devidas, John H. Healey

Publikováno v: Pediatric Blood & Cancer. 63:54-61

Background Although chemotherapy has improved outcome of osteosarcoma, 30–40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardiopr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14e32ff5353c72f1b711fce324476317
https://doi.org/10.1002/pbc.25753

Zobrazit plný text záznamu

Phase 2 Trial of Recombinant Tumor Necrosis Factor-α in Combination With Dactinomycin in Children With Recurrent Wilms Tumor

Autor: John Kelleher, Judith K. Sato, Junfeng Sun, Paul M. Sondel, Holly J. Meany, Jerry Z. Finklestein, Nita L. Seibel, Gregory H. Reaman

Publikováno v: Journal of Immunotherapy. 31:679-683

Tumor necrosis factor (TNF), a peptide produced by macrophages with cytostatic and cytolytic effects, demonstrated single agent antitumor activity and synergistic effect when administered with dactinomycin in in vitro tumor cell lines, in vivo xenogr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abfcc0594480c0a111bb80f7beafcdf4
https://doi.org/10.1097/cji.0b013e3181826d72

Zobrazit plný text záznamu

High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors

Autor: Stephen J. Forman, Peter M. Falk, C. Oliver, Judith K. Sato, Anna B. Pawlowska, James S. Miser, Marianna Shakhnovits, E. Bolotin, Joseph Rosenthal, Dajun Qian

Publikováno v: Bone Marrow Transplantation. 42:311-318

The purpose of the study was to evaluate the feasibility and safety of two cycles of high-dose chemotherapy (HDT) followed by autologous hematopoietic SCT (HSCT) in patients with poor prognosis Ewing family of tumors (EFT). Twenty patients with prima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dea2c3545d54996ffe13a7b0cf6745f
https://doi.org/10.1038/bmt.2008.169

Zobrazit plný text záznamu

A phase 2 trial of all-trans-retinoic acid in combination with interferon-α2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study

Autor: Gregory H. Reaman, Judith K. Sato, Frank M. Balis, Peter C. Adamson, Katherine K. Matthay, Michelle O'Brien

Publikováno v: Pediatric Blood & Cancer. 49:661-665

Background The combination of the antiproliferative and differentiation-inducing effects of retinoids together with the antiproliferative, immunostimulatory, and differentiation-potentiating effects of interferon-α (IFN-α) were the basis for the de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f92478b852833eec6df4878f5f96f1a
https://doi.org/10.1002/pbc.21011

Zobrazit plný text záznamu

Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

Autor: Cindy L, Schwartz, Leonard H, Wexler, Mark D, Krailo, Lisa A, Teot, Meenakshi, Devidas, Laurel J, Steinherz, Allen M, Goorin, Mark C, Gebhardt, John H, Healey, Judith K, Sato, Paul A, Meyers, Holcombe E, Grier, Mark L, Bernstein, Steven E, Lipshultz

Publikováno v: Pediatric bloodcancer. 63(1)

Although chemotherapy has improved outcome of osteosarcoma, 30-40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardioprotectant dexr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0a5a5fd3481f6b97f32a4bcef7f6d5a3
https://pubmed.ncbi.nlm.nih.gov/26398490

Zobrazit plný text záznamu

Prospective Randomized Trial Between Two Doses of Granulocyte Colony-Stimulating Factor After Ifosfamide, Carboplatin, and Etoposide in Children With Recurrent or Refractory Solid Tumors: A Children's Cancer Group Report

Autor: Gregory H. Reaman, Sharon Frierdich, Mitchell S. Cairo, Julie Blatt, Bruce R. Blazar, Violet Shen, Mark Krailo, Wen Liu-Mares, Judith K. Sato, Madeline Bauer, James S. Miser

Publikováno v: Journal of Pediatric Hematology/Oncology. 23:30-38

PurposeThe objectives of this study were[colon] 1) to compare the time to hematologic recovery (absolute neutrophil count [lsqb]ANC[rsqb] [ge]1,000/mm3 and platelet count [ge]100,000/mm3) in a randomized prospective study of two doses of granulocyte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4a4fb50167d4ecdbd2e627aceda6a49
https://doi.org/10.1097/00043426-200101000-00008

Zobrazit plný text záznamu

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group

Autor: Susan R. Wiersma, Gregory H. Reaman, Mark Krailo, Wen Liu-Mares, Patricia A. Dinndorf, Vassilios I. Avramis, J F Kelleher, Revonda B. Mosher, Judith K. Sato, Nita L. Seibel

Publikováno v: Journal of Clinical Oncology. 15:2780-2785

PURPOSE The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in children with relapsed or refractory leukemia. The phase I study was extended to a lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f26edecbbacb9e3d5976789b7399fde
https://doi.org/10.1200/jco.1997.15.8.2780

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání